Imagion Biosystems Advances Cancer Imaging Programs with FDA and Strategic Partnerships

Imagion Biosystems Ltd. ( (AU:IBX) ) has issued an update.

Imagion Biosystems Ltd. has made significant progress in its MagSense® HER2 breast cancer imaging agent program, aiming to file an Investigational New Drug (IND) application for a Phase 2 clinical trial with the FDA in the third quarter of 2025. The company received positive feedback from the FDA, boosting confidence in the IND submission. Additionally, Imagion has entered into a Master Service Agreement with Biosensis Ltd. to manage costs and advance nanoparticle research, and appointed Dr. Leonardo Kayat-Bittencourt as a clinical advisor for its prostate cancer program. The company is also preparing for the manufacturing of the MagSense® HER2 imaging agent and has selected Dr. William Dooley as the Principal Investigator for the upcoming study. Financially, Imagion reported a decrease in cash balance and operating cash outflows, with plans to reduce corporate costs and focus funds on the IND application.

More about Imagion Biosystems Ltd.

Imagion Biosystems Ltd. operates in the healthcare industry, focusing on the early detection of cancer through its proprietary MagSense® imaging technology. The company aims to improve healthcare outcomes by developing imaging agents for cancer detection, with a market focus on breast and prostate cancer diagnostics.

Average Trading Volume: 4,523,152

Technical Sentiment Signal: Sell

Current Market Cap: A$3.52M

See more insights into IBX stock on TipRanks’ Stock Analysis page.